Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Verastem’s value play

How Verastem parlayed duvelisib deal into a $54 million market cap bump

Stephen Hansen, Associate Editor
September 8, 2017 9:54 PM UTC

Verastem Inc. (NASDAQ:VSTM) has parlayed a small gamble on Phase III asset duvelisib into a double-digit stock bump and what could become the company’s first commercial product.

Verastem soared $1.08 (28%) to $4.92 on Sept. 6, adding $40 million in market cap, after announcing duvelisib met the primary endpoint of progression-free survival (PFS) in the Phase III DUO study to treat relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Verastem Inc.